Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

@article{Zhou2009PolymorphismOH,
  title={Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance},
  author={Shufeng Zhou},
  journal={Clinical Pharmacokinetics},
  year={2009},
  volume={48},
  pages={689-723}
}
  • Shufeng Zhou
  • Published 2009
  • Biology, Medicine
  • Clinical Pharmacokinetics
Cytochrome P450 (CYP) 2D6 is one of the most investigated CYPs in relation to genetic polymorphism, but accounts for only a small percentage of all hepatic CYPs (∼2–4%). There is a large interindividual variation in the enzyme activity of CYP2D6. The enzyme is largely non-inducible and metabolizes ∼25% of current drugs. Typical substrates for CYP2D6 are largely lipophilic bases and include some antidepressants, antipsychotics, antiarrhythmics, antiemetics, β-adrenoceptor antagonists (β-blockers… 
Complexities of CYP2D6 gene analysis and interpretation
  • A. Gaedigk
  • Medicine
    International review of psychiatry
  • 2013
TLDR
A summary of the intricacies of CYP2D6 variation and genotype analysis is provided, knowledge that is invaluable for the translation of genotype into clinically useful information.
Is CYP2D6 phenotype predictable from CYP2D6 genotype
TLDR
CYP2D 6 genotyping for the most frequent allelic variants was able to reliably predict CYP2D6 phenotypes in most donors; however, the external factors modifying the phenotypic appearance of CYP1D6 had to be taken into account.
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
TLDR
CYP2D6 phenotyping and genotyping appear to be useful in predicting steady-state concentrations of some classical antipsychotic drugs, but their usefulness in predicting clinical effects must be explored.
How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments.
TLDR
Some of the different methodological approaches used to screen for CYP2D6 variants are reported and methods that have improved variation detection are focused on, from conventional techniques to more recent microarray technology and high throughput DNA sequencing.
Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro
  • Zhe Wang, L. Wang, +5 authors G. Hu
  • Biology, Medicine
    Drug design, development and therapy
  • 2016
TLDR
The present data in vitro suggest that the newly found variants significantly reduced catalytic activities compared with CYP2D6.1.2, which is greatly relevant to personalized medicine.
CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects.
The CYP2D6 enzyme contributes to the metabolism and bioactivation of approximately a quarter of drugs clinically used, including many antidepressants and antipsychotics, codeine and tramadol
CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects.
The CYP2D6 enzyme contributes to the metabolism and bioactivation of approximately a quarter of drugs clinically used, including many antidepressants and antipsychotics, codeine and tramadol
CYP2D6 variability in populations from Venezuela
TLDR
There is a considerable amount of work remaining before CYP2D6 is integrated into clinical practice in Venezuela, and it is necessary to increase research in this regard, in particular to develop studies with a larger sample size.
Effects of 24 CYP2D6 Variants Found in the Chinese Population on the Metabolism of Risperidone
TLDR
This is the first report of all these novel alleles for risperidone metabolism, providing fundamental data for further clinical studies on CYP2D6 alleles.
Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations
TLDR
The CYP2D6 genotype seemed to be an important determinant of galantamine pharmacokinetics, with CYP 2D6 poor metabolizers presenting 45% and 61% higher dose-adjusted galantamines plasma concentrations than heterozygous and homozygous CYP3A extensive metabolizers.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 747 REFERENCES
Polymorphisms in the CYP 2D6 Gene: Association with Plasma Concentrations of Fluoxetine and Paroxetine
TLDR
It is found that plasma concentration of the antidepressant drugs was significantly correlated with genetic status and in PM fluoxetine-treated patients, drug plasma concentration was significantly higher than that seen in extensive metabolizers.
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
TLDR
Predictive CYP2D6 genotyping is estimated by the author to be beneficial for treatment of about 30–40% of CYP 2D6 drug substrates, that is, for about 7–10% of all drugs clinically used, although prospective clinical studies are necessary to evaluate the exact benefit of drug selection and dosage.
Polymorphism of human cytochrome P450 enzymes and its clinical impact
TLDR
Current pharmacogenetic knowledge on important human drug-metabolizing cytochrome P450s (CYPs) is highlighted to understand the large interindividual variability in drug clearance and responses in clinical practice and to improve the efficacy and safety of both prospective and currently available drugs.
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
TLDR
General biomolecular and pharmacological features are summarized and a detailed up-to-date description of genetic polymorphisms are presented, including a discussion of recent clinical applications of CYP2B6 pharmacogenetics.
Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication
  • I. Cascorbi
  • Medicine
    European journal of clinical investigation
  • 2003
TLDR
Since there is evidence that deteriorated drug elimination partly accounts for drug side‐effects, CYP2D6 genotyping could contribute to an individualized and therefore optimized drug therapy.
Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
TLDR
There are mixed effects on the functionally reduced allelic variants in enzyme-substrate affinity or enzyme-inhibitor affinity, which is lower, higher, or comparable to that for CYP2D6.1.
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
TLDR
It is concluded that the pharmacogenetic knowledge regarding CYP polymorphism now developed to a stage where it can be implemented in drug development and in clinical routine for specific drug treatments, thereby improving the drug response and reducing costs for drug treatment.
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
TLDR
A solid basis is provided for prediction of CYP2D6 capacity, as required in drug research and routine drug treatment, and significant differences in enzymatic activity measured by the dextromethorphan metabolic ratio (MR) are shown.
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
TLDR
An overview of the history and application of CYP2D6 pharmacogenetics is provided, and the clinical implications of recent developments relating to the involvement of CY P450 2D6 in tamoxifen treatment are discussed.
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
TLDR
The intricate genetics of the CYP2D6 polymorphism is becoming apparent at ever greater detail, applications in clinical practice are still rare, and more clinical studies are needed to show where patients benefit from drug dose adjustment based on their genotype.
...
1
2
3
4
5
...